新型抗栓药物替格瑞洛在急性冠脉综合征治疗中的应用研究进展

Research progress in application of new antithrombtic drug Ticagrelor in treatment of acute coronary syndrome

急性冠脉综合征(ACS)是威胁人类健康的重大疾病。双联抗血小板治疗是ACS患者治疗的基石。氯吡格雷作为经典的抗血小板药物,在临床应用的过程中显现出许多不足,替格瑞洛由于其特殊的药代动力学和药效学特征,克服了氯吡格雷的缺陷,国内外许多大型临床研究已经证实在治疗ACS患者中的优越性,极大地降低了ACS患者的主要不良心血管事件。新的研究不断问世,为替格瑞洛提供了大量的循证医学证据。本文将对替格瑞洛的药理学特征、目前的临床研究及相应的指南作一综述。

Acute coronary syndrome （ACS） is a severe disease which threatens human health. Dual antiplatelet is the cornerstone of the treatment of ACS. Clopidogrel, as a classical antiplatelet drug, has showed several flaws. However,Ticagrelor, a new antithrombtic drug, overcomes those deficiencies thanks to its special pharmacokinetic and pharmacodynamics characteristics. Many large clinical studies have confirmed the advantages of Ticagrelor in treatment of ACS patients with acute coronary syndrome as it greatly reduces the major cardiac events in ACS patients. New studies have provided a large number of evidence-based medical evidence and this paper is to review the pharmacological characteristics, current clinical studies and corresponding guidelines of Ticagrelor.